Biodexa Secures Syngene Partnership for MTX240 Clinical Trial Manufacturing
BDRX is trading near its 52-week low of $0.601 (11% above the low) on light trading volume (0.1× avg).
Summary
Biodexa Pharmaceuticals has announced a partnership with Syngene International for the manufacturing of MTX240 active pharmaceutical ingredient and dosage form, which will supply GMP clinical trial supplies. This agreement is a critical operational step in advancing MTX240, a molecular glue technology for Gastrointestinal Stromal Tumors (GIST), towards its planned Phase 1b/2a study later this year. The partnership demonstrates continued execution on a key pipeline asset, especially following the recent licensing of MTX240 from Otsuka in February. This development provides a positive operational update for the micro-cap company, which recently reported a significant net loss and "substantial doubt" about its ability to continue as a going concern, indicating ongoing progress despite financial challenges.
At the time of this announcement, BDRX was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.60 to $19.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.